SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Delays in New Drug Applications in Japan and Industrial R&D Strategies
3 references·3 citing·21 second hop
Delays in New Drug Applications in Japan and Industrial R&D Strategies (2009)Delays in New Drug Applications in Japan …The role of firm characteristics in pharmaceutical product launches (2006)The role of firm characterist…The impact of price regulation on the launch delay of new drugs—evidence from twenty‐five major markets in the 1990s (2004)The impact of price regulatio…Can the pharmaceutical industry reduce attrition rates? (2004)Can the pharmaceutical indust…Regulatory review of new product innovation: Conceptual clarity and future research directions (2021)Regulatory review of new prod…Evolving Landscape of New Drug Approval in Japan and Lags from International Birth Dates: Retrospective Regulatory Analysis (2020)Evolving Landscape of New Dru…Recent trends for drug lag in clinical development of oncology drugs in Japan: does the oncology drug lag still exist in Japan? (2015)Recent trends for drug lag in…The price of innovation: new estimates of drug development costs (2003)How to improve R&D productivity: the pharmaceutical industry's grand challenge (2010)Diagnosing the decline in pharmaceutical R&D efficiency (2012)Clinical development success rates for investigational drugs (2014)Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations (2010)Significant Differences in Drug Lag in Clinical Development Among Various Strategies Used for Regulatory Submissions in Japan (2013)MONOPOLISTIC COMPETITION AND OPTIMUM PRODUCT DIVERSITY (1975)Entry and Competition in Concentrated Markets (1991)The Regulation of Entry (2000)Patents, Price Controls, and Access to New Drugs: How Policy Affects Global Market Entry (2005)Entry and Patenting in the Software Industry (2011)Effects of Regulation on Drug Launch and Pricing in Interdependent Markets (2012)An Evaluation of Consumer Protection Legislation: The 1962 Drug Amendments (1973)Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and Patents (2003)Pharmaceutical Price Controls and Entry Strategies (2007)Market size and pharmaceutical innovation (2015)Regulatory Review of New Therapeutic Agents — FDA versus EMA, 2011–2015 (2017)An Evolutionary Theory of Economic Change. (1983)Towards a Methodology for Developing Evidence‐Informed Management Knowledge by Means of Systematic Review (2003)Understanding dynamic capabilities (2003)The three pointers of research and development (R&D) for growth-boosting sustainable innovation system (2022)
this work references cited by second hop

References

  • 2004Can the pharmaceutical industry reduce attrition rates?4,230 cited
  • 2004The impact of price regulation on the launch delay of new drugs—evidence from twenty‐five major markets in the 1990s344 cited
  • 2006The role of firm characteristics in pharmaceutical product launches105 cited

Cited by

  • 2020Evolving Landscape of New Drug Approval in Japan and Lags from International Birth Dates: Retrospective Regulatory Analysis51 cited
  • 2015Recent trends for drug lag in clinical development of oncology drugs in Japan: does the oncology drug lag still exist in Japan?50 cited
  • 2021Regulatory review of new product innovation: Conceptual clarity and future research directions26 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work